Patent US3765023A successfully refreshed from Google Patents.
US4602008A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent
Assignee: Astex Pharmaceuticals Inc
•
Filing: 1984-12-14
•
Granted: 1986-07-22
•
Expires: 2004-12-14
Abstract
Abstract 16-Alkylated and 16-alkylated-7-hydroxy 5β-androstan-3-ol-17-one, and the esters and ethers thereof, are used as an anti-diabetic, anti-obesity and erythropoietic agent in mammals.
Inventors
- 👤 George Krsek
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 21:21
CPC Classifications
C; C07; C07J; C07J9/00; A; A61; A61K; A61K31/00; A61K31/56; A61K31/565; C07J1/00; C07J1/0003; C07J1/0011
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
13 words
A compound selected from the group consisting of 16-methylene-5β-androstan-3α-ol-17-one, and 16-methylene-5β-androstan-3α,7α-diol-17-one, and 16-methyl-5β-androstan-3α,7α-diol-17-one.
Claim 2
Dependent Claim
13 words
A compound selected from the group consisting of 16-methylene-5β-androstan-3α-ol-17-one, and 16-methylene-5β-androstan-3α,7α-diol-17-one, and 16-methyl-5β-androstan-3α,7α-diol-17-one.
Claim 3
Dependent Claim
6 words
16-methylene-5β-androstan-3α-ol-17-one in accordance with claim 1.
Claim 4
Dependent Claim
6 words
16-methylene-5β-androstan-3α,7α-diol-17-one in accordance with claim 1.
Claim 5
Dependent Claim
6 words
16-methyl-5β-androstan-3α,7α-diol-17-one in accordance with claim 1.
Claim 6
Dependent Claim
32 words
A method of inducing an anti-diabetic, anti-obesity or erythropoietic effect in a mammal which comprises administering to the mammal an anti-diabetic, anti-obesity or erythropoietic effective amount of a compound of claim 1.
Claim 7
Dependent Claim
10 words
The method of claim 5, wherein said administration is oral.
Claim 8
Dependent Claim
16 words
The method of claim 5, wherein the amount administered is about 100-4,000 mg per 70 kilos.
Claim 9
Dependent Claim
12 words
The method of claim 7, wherein the amount is about 500-1,000 mg.
Claim 10
Dependent Claim
10 words
The method of claim 5, wherein the administration is parenteral.
Claim 11
Dependent Claim
19 words
The method of claim 9, wherein the amount of administration is about 700-2,000 mg per 70 kilos per day.
Claim 12
Dependent Claim
11 words
The method of claim 10, wherein the amount is 900-1,100 mg.
Claim 13
Dependent Claim
11 words
The method of claim 5, wherein said compound is and 16-methylene-5β-androstan-3α-ol-17-one.
Claim 14
Dependent Claim
10 words
The method of claim 5, wherein said compound is 16-methylene-5β-androstan-3α,7α-diol-17-one.
Claim 15
Dependent Claim
23 words
A composition comprising an anti-diabetic, anti-obesity or erythropoietic effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
Claim 16
Dependent Claim
16 words
The composition of claim 14, wherein each unit dose contains about 100-1,000 mg of said compound.
Claim 17
Dependent Claim
13 words
The composition of claim 15, wherein each unit dose contains about 200-400 mg.
Claim 18
Dependent Claim
10 words
The composition of claim 14, wherein said compound is 16-methylene-5β-androstan-3α-ol-17-one.
Claim 19
Dependent Claim
10 words
The compound of claim 14, wherein said compound is 16-methylene-5β-androstan-3α,7α-diol-17-one.
References Cited (Backward Citations)
US4507289A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-07-21 | 1990-01-20 | 1990-07-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-07-21 | 1994-01-20 | 1994-07-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-07-21 | 1998-01-20 | 1998-07-22 | $7700.00 | Window Closed / Lapsed |